Eledon Pharmaceuticals, Inc. (ELDN)
3.20
-0.12
(-3.61%)
USD |
NASDAQ |
Aug 28, 16:00
3.21
+0.01
(+0.31%)
After-Hours: 20:00
Eledon Pharmaceuticals Cash from Operations (Quarterly) : -22.68M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -22.68M |
| March 31, 2026 | -22.61M |
| December 31, 2025 | -14.09M |
| September 30, 2025 | -14.48M |
| June 30, 2025 | -17.71M |
| March 31, 2025 | -16.06M |
| December 31, 2024 | -18.99M |
| September 30, 2024 | -11.77M |
| June 30, 2024 | -7.774M |
| March 31, 2024 | -8.741M |
| December 31, 2023 | -9.131M |
| September 30, 2023 | -12.25M |
| June 30, 2023 | -8.221M |
| March 31, 2023 | -9.924M |
| December 31, 2022 | -9.48M |
| September 30, 2022 | -4.571M |
| June 30, 2022 | -6.217M |
| March 31, 2022 | -8.156M |
| December 31, 2021 | -9.208M |
| September 30, 2021 | -7.093M |
| June 30, 2021 | -7.446M |
| March 31, 2021 | -5.166M |
| December 31, 2020 | -9.433M |
| September 30, 2020 | -0.561M |
| June 30, 2020 | -3.021M |
| Date | Value |
|---|---|
| March 31, 2020 | -2.197M |
| December 31, 2019 | -2.023M |
| September 30, 2019 | -2.889M |
| June 30, 2019 | -4.922M |
| March 31, 2019 | -4.023M |
| December 31, 2018 | -3.353M |
| September 30, 2018 | -2.935M |
| June 30, 2018 | -3.334M |
| March 31, 2018 | -2.271M |
| December 31, 2017 | -2.611M |
| September 30, 2017 | -3.417M |
| June 30, 2017 | -8.031M |
| March 31, 2017 | -0.882M |
| December 31, 2016 | -1.282M |
| September 30, 2016 | -1.479M |
| June 30, 2016 | 7.578M |
| March 31, 2016 | -9.74M |
| December 31, 2015 | -8.877M |
| September 30, 2015 | -10.25M |
| June 30, 2015 | -11.00M |
| March 31, 2015 | -11.10M |
| December 31, 2014 | -6.46M |
| September 30, 2014 | -4.464M |
| June 30, 2014 | -5.421M |
| March 31, 2014 | -4.776M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 1.125B |
| Viking Therapeutics, Inc. | -125.17M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 23.24M |
| Cash from Financing (Quarterly) | 0.091M |
| Free Cash Flow | -73.86M |
| Free Cash Flow Per Share (Quarterly) | -0.1996 |
| Free Cash Flow to Equity (Quarterly) | -22.59M |
| Free Cash Flow to Firm (Quarterly) | -22.68M |
| Free Cash Flow Yield | -24.38% |